When Growth Teams Flail: A Common Starting Point
Many mid-sized medical-device companies call in growth teams expecting instant revenue lifts. Instead, they get frustration. One global firm with a $300 million orthopedic device unit built a growth squad that churned through campaigns but saw flat lead-to-opportunity rates over 18 months. The culprit: unclear ownership of key metrics and friction between sales and marketing.
You often see this gap when growth teams focus too much on acquisition channels—paid search, email blasts—without syncing with clinical sales reps or regulatory affairs. The result? Marketing efforts that don’t feed qualified leads into the pipeline. A 2024 PharmaGrowth Insights report showed 62% of medical-device firms’ growth projects stall due to misaligned internal functions.
Diagnosing Role Ambiguity in Growth Teams
Growth teams that lack defined roles are a frequent trouble spot. In one case, a cardiovascular device maker deployed a growth “pod” where product managers doubled as growth leads and data analysts. This multitasking led to missed deadlines and inconsistent messaging.
Separating functions—growth lead, data analyst, campaign strategist—cuts confusion. This isn’t just a luxury: it saves months of rework. Tools like Zigpoll and Qualtrics surveys can help identify role clarity issues by polling internal stakeholders regularly. One team used Zigpoll quarterly to measure alignment, which nudged them to clarify roles within 3 months and improved project velocity by 20%.
Misaligned Metrics Kill Momentum
A common trap: growth teams track vanity metrics instead of actionable business KPIs. For example, a firm measuring newsletter opens without correlating to device demo requests will spin its wheels.
The fix is to tie growth metrics directly to sales pipeline health and regulatory milestones. One respiratory device company tracked demo requests, FDA submission readiness, and sales-qualified leads. This shift boosted conversion rates from 2% to 11% over a year. But remember: this approach requires data integration between CRM, marketing automation, and regulatory tracking systems—a technical hurdle that can frustrate teams.
Siloed Growth Teams vs. Integrated Functions
Growth teams that operate as isolated marketing groups misfire in pharmaceutical device companies. Clinical education, customer success, and regulatory affairs must be part of the feedback loop. Without this, companies risk wasting budgets on leads that never progress due to clinical constraints or regulatory delays.
A leading neurotechnology firm integrated growth with clinical liaisons and saw a 35% higher lead qualification rate. They held weekly syncs where regulatory updates and clinical trial progress were discussed alongside campaign results. This level of integration requires discipline and openness; it’s not common in established pharma cultures.
Experimentation Without Guardrails: More Harm Than Good
Another failure mode: growth teams run multiple experiments blindly, flooding clinical sales with irrelevant leads. One firm ran 10 A/B tests on messaging but ignored that their sales reps were overwhelmed by unqualified leads.
Setting up guardrails—like lead scoring thresholds and feedback loops with sales—is critical. Using tools like Zigpoll or Medallia to gather rep feedback on lead quality can help. In practice, limiting experiments to two or three parallel streams and incorporating sales feedback weekly may be more productive than chasing novelty.
Overcentralized Decision-Making Slows Growth
In several mid-sized devices companies, growth teams report into centralized marketing functions that require multiple approvals for simple pivots. This bottleneck costs agility. At a firm producing diabetes-monitoring devices, this resulted in a 4-month lag before campaign adjustments, leading to lost sales opportunities.
Delegating decision rights to growth teams within predefined boundaries accelerates fixes. One example: a cardiac device company reduced campaign iteration time from 12 weeks to 4 by empowering growth leads with budget and messaging autonomy, provided compliance checks were routine.
Underinvesting in Data Infrastructure
Growth teams in pharma often fail because they can’t access clean, integrated data fast enough to diagnose issues. Disparate CRM, regulatory, and clinical trial data systems create blind spots.
A top-tier spinal implant company rebuilt its data stack to integrate Salesforce, Veeva CRM, and their regulatory database. This enabled real-time dashboards linking growth activities to FDA approval statuses. Result: a 25% increase in pipeline velocity attributed directly to improved data visibility.
However, this requires investment and patience; not every organization has the resources for this upfront.
Leadership Disconnect Undermines Growth Team Authority
Even well-structured growth teams can stumble if senior management sees them as “marketing projects” rather than strategic growth drivers. This often results in underfunding and lack of cross-department support.
In one example, a diabetes device maker’s growth team struggled to get clinical trial teams to prioritize customer feedback gleaned from growth experiments. After executive workshops reframed growth as cross-functional, collaboration improved measurably.
Case Study: How a Mid-Sized Neurotech Firm Fixed Growth Team Failures
A neurotechnology firm with $120 million in sales had a growth team spinning wheels for 18 months—no increase in qualified leads despite a $1.2 million budget. The team faced unclear roles, misaligned metrics, and poor data access.
Actions taken:
Defined roles clearly: growth lead, data analyst, clinical liaison, content specialist.
Shifted metrics to lead qualification tied to clinical trial readiness.
Integrated clinical and regulatory teams into weekly scrums.
Invested in data integration between Veeva CRM and internal regulatory systems.
Enabled near real-time feedback from sales reps via Zigpoll surveys.
Results after 12 months:
Qualified leads increased by 75%.
Conversion from lead to opportunity rose from 3% to 9%.
Pipeline velocity improved 30%.
Team morale ratings (via internal polls) increased 40%.
Caveat: The upfront investment in data and team alignment took 6 months before results appeared. This approach won’t work in under-resourced or highly siloed organizations.
What Didn’t Work: Chasing More Channels
The firm initially tried launching multiple new acquisition channels simultaneously—social media, webinars, paid search—without fixing internal alignment and data issues. This diluted efforts and created measurement chaos. Cutting back and focusing on core, validated channels produced better ROI.
Summary Table of Common Growth Team Failures and Fixes
| Failure Mode | Root Cause | Fix | Impact Example |
|---|---|---|---|
| Unclear roles | Overlapping duties, no ownership | Define roles, use internal surveys (Zigpoll) | Improved velocity by 20% |
| Misaligned metrics | Tracking vanity KPIs | Tie metrics to sales pipeline/clinical KPIs | Conversion 2% → 11% (respiratory device) |
| Siloed functions | Lack of integration with clinical/reg | Weekly cross-functional syncs | Lead qualification +35% |
| Experimentation overload | No feedback loops | Limit experiments; gather sales feedback | Lead quality improved |
| Centralized approvals | Slow decision-making | Delegate authority with compliance guardrails | Campaign iteration 12w → 4w |
| Poor data infrastructure | Disparate systems | Invest in data integration | Pipeline velocity +25% |
| Leadership disconnect | Growth seen as marketing-only | Executive buy-in and alignment workshops | Cross-team collaboration improved |
Final Reflection
Growth teams in pharmaceutical medical-device firms rarely fail for lack of ideas. They stumble because of misalignment: unclear roles, poor data, misdefined metrics, and siloed teams. Mid-level general management must insist on precise role definitions, integrated data systems, and metrics that connect growth activities to sales and regulatory realities. The temptation to chase new channels before fixing fundamentals should be resisted.
Remember, your growth team is a connector—not just a campaign machine. Fix the plumbing before adding more taps.
